Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageDebt RatioDebt to EquityEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginGross MarginInterest Coverage RatioInventory AverageInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Invested CapitalReturn on SalesTimes Interest Earned

Immunocore Holdings (IMCR) Gross Margin (2023 - 2025)

Immunocore Holdings' Gross Margin history spans 3 years, with the latest figure at 97.41% for Q4 2025.

  • For Q4 2025, Gross Margin fell 219.0% year-over-year to 97.41%; the TTM value through Dec 2025 reached 98.73%, down 39.0%, while the annual FY2025 figure was 98.73%, 39.0% down from the prior year.
  • Gross Margin for Q4 2025 was 97.41% at Immunocore Holdings, down from 99.51% in the prior quarter.
  • Across five years, Gross Margin topped out at 99.71% in Q4 2023 and bottomed at 97.41% in Q4 2025.
  • The 3-year median for Gross Margin is 99.47% (2024), against an average of 99.14%.
  • The largest YoY upside for Gross Margin was 120bps in 2025 against a maximum downside of -219bps in 2025.
  • A 3-year view of Gross Margin shows it stood at 99.71% in 2023, then fell by 0bps to 99.61% in 2024, then fell by -2bps to 97.41% in 2025.
  • Per Business Quant, the three most recent readings for IMCR's Gross Margin are 97.41% (Q4 2025), 99.51% (Q3 2025), and 98.94% (Q2 2025).